Translational Biomarkers and Therapeutic Development for Very Young Children Diagnosed With Autism Spectrum Disorder and Co-occurring Anxiety
Abstract
A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change).
Conditions: Autism, Autism Spectrum Disorder.
Primary outcome: Spence Preschool Anxiety Scale (SPAS) or Spence Anxiety Scale (SCAS) Parent Report.
Enrollment: 30 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 30 participants or records.
Read the paper
Related studies
- Diarylethenes for Memories and Switches
- Long-Term Potentiation and Memory
- Social Memory Studies: From “Collective Memory” to the Historical Sociology of Mnemonic Practices
- The Cognitive Neuroscience of Working Memory
- Memory aging and brain maintenance
- Effector and Memory CTL Differentiation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.